Fig. 7From: A novel formulation of theranostic nanomedicine for targeting drug delivery to gastrointestinal tract cancerAntigastric cancer efficacy of GNP theranostic nanomedicines during treatment in vivo. a The survival rates (%) of the three groups of induced gastric cancer mice during 40Â days treatment in the ten mice in each group and b the changes in body weight of different groups of mice over the period of 15Â days observationsBack to article page